Dernière mise à jour : 02 septembre 2016
Détails
FichiersGeneric Name:
Arsenic Trioxide
État du projet:
Terminé
Domaine thérapeutique:
Acute Promyelocytic Leukemia
Fabricant:
Lundbeck Canada Inc.
Brand Name:
Trisenox
Gamme de produits:
Examen en vue du remboursement
Numéro de projet :
PC0033-000
Indicateur de rendement:
S. O. – Mesures de rendement prédictives
Strength:
1 mg/mL
Tumour Type:
Leukemia
Indications:
Acute Promyelocytic Leukemia
Funding Request:
For patients who were refractory to or relapsed from previous treatment and newly diagnosed APL patients who have received no prior treatment
Review Status:
Complete
Date NOC Issued:
Sponsor:
Lundbeck Canada Inc.
Submission Date:
Submission Deemed Complete:
Priorisation demandée:
Demandée et accordée
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommandation:
Couvrir le remboursement
pERC Meeting:
Final Recommendation Issued:
Fichiers
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
Dernière mise à jour : 02 septembre 2016